A surge of investment interest in companies developing hair loss treatments in the U.S. market has led to a strong performance by Hyundai Pharmaceutical in early trading.
As of 10:15 a.m. on September 7, Hyundai Pharmaceutical's shares rose by 680 won (8.5%) to 8,630 won, according to the Korea Exchange.
The increase in Hyundai Pharmaceutical's stock price is attributed to the recent strong performance of hair loss treatment companies in the U.S. Bloomberg reported on August 29 that these companies have become a new focus for investors on Wall Street, following interest in obesity treatments. For instance, shares of U.S.-based Veradermix have skyrocketed nearly 500% since its listing in February, reflecting the rising stock prices of companies in the hair loss treatment sector.
Hyundai Pharmaceutical is one of the leading developers of hair loss treatments, known for its minoxidil-based product line, including the brand 'Minoxidil.' The company offers various hair loss treatments, such as Minoxidil solution in 3% and 5% concentrations, a 5% gel, and a combination Minoxidil solution. Last year, it launched the 'Minoxidil Foam 5% Aerosol,' which contains 5% minoxidil.
Other companies in the KOSDAQ market are also experiencing significant gains, including JW Pharmaceutical (up 12.1%) and Samik Pharmaceutical (up 29.7%). JW Pharmaceutical sells oral hair loss treatments 'Monad' containing finasteride and 'Dutamoa' containing dutasteride. Meanwhile, Samik Pharmaceutical has developed a technology to convert its existing daily oral treatment for alopecia areata into a once-a-month injectable treatment using baricitinib (a JAK inhibitor), which was introduced in January.
As of 10:15 a.m. on September 7, Hyundai Pharmaceutical's shares rose by 680 won (8.5%) to 8,630 won, according to the Korea Exchange.
The increase in Hyundai Pharmaceutical's stock price is attributed to the recent strong performance of hair loss treatment companies in the U.S. Bloomberg reported on August 29 that these companies have become a new focus for investors on Wall Street, following interest in obesity treatments. For instance, shares of U.S.-based Veradermix have skyrocketed nearly 500% since its listing in February, reflecting the rising stock prices of companies in the hair loss treatment sector.
Hyundai Pharmaceutical is one of the leading developers of hair loss treatments, known for its minoxidil-based product line, including the brand 'Minoxidil.' The company offers various hair loss treatments, such as Minoxidil solution in 3% and 5% concentrations, a 5% gel, and a combination Minoxidil solution. Last year, it launched the 'Minoxidil Foam 5% Aerosol,' which contains 5% minoxidil.
Other companies in the KOSDAQ market are also experiencing significant gains, including JW Pharmaceutical (up 12.1%) and Samik Pharmaceutical (up 29.7%). JW Pharmaceutical sells oral hair loss treatments 'Monad' containing finasteride and 'Dutamoa' containing dutasteride. Meanwhile, Samik Pharmaceutical has developed a technology to convert its existing daily oral treatment for alopecia areata into a once-a-month injectable treatment using baricitinib (a JAK inhibitor), which was introduced in January.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.